About Group Pharmaceuticals Limited
Data last updated:
Group Pharmaceuticals Limited is a public limited company based in Thane, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 24 July 1980 and has been in existence for over 46 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24239MH1980PLC022889. Its GSTIN is 27AAACG8723H1ZK (Maharashtra). The company holds 12 GST registrations, of which 2 are active.
The company has an authorised share capital of ₹25 Cr and a paid-up capital of ₹12.68 Cr. It was formerly known as Group Pharmaceuticals Private Limited. It is led by directors including Deepak Mohan (Managing Director) and Ann Valerie Sunil Attavar (Whole-Time Director).
Its last annual general meeting (AGM) was held on 26 July 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at W – 46 (B) M I D Ctarapur Industrial Area, Thane, Maharashtra, India – 401506.
As per the financials filed for FY 2025, the company reported a revenue of ₹168.31 Cr, a growth of 10% compared to the previous year. For the same year it recorded a net profit of ₹10.44 Cr (net margin 6.2%) and EBITDA of ₹15.78 Cr (EBITDA margin 9.4%). Revenue has grown at a compounded annual rate (CAGR) of 9% over three years and 6% over five years.
The company has about 739 employees on its provident fund (EPFO) records.
The company is associated with 2 brands: Group Pharma and Group Pharmaceuticals Ltd. As per MCA filings, the company has open charges of ₹20 Cr and satisfied charges of ₹31.62 Cr on record. Court records list 48 cases involving the company, including 28 filed by the company and 15 filed against it; 4 cases are pending. The company has 3 deals on record (2 acquisitions, 1 rights issue); the latest was in September 2026. Its 10 peer companies in the Pharma industry (Formulations, Pharmaceuticals) are compared by revenue, 5 larger and 5 smaller; the largest is Shree Krishnakeshav Laboratories Limited with revenue of ₹170.52 Cr. The company has 14 MSME Form 1 returns on record between 2019 and 2024, listing 367 overdue payments to 44 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website grouppharma.in.
- EmailLocked
- TelephoneLocked
- Website
- Social Media
- Registered AddressW – 46 (B) M I D Ctarapur Industrial Area, Thane, Maharashtra, India – 401506
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Group Pharmaceuticals Limited
The main business activity of Group Pharmaceuticals is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Group Pharmaceuticals Limited FY 2025 filings available
Group Pharmaceuticals Limited reported revenue of ₹168.31 Cr (up 10% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of Group Pharmaceuticals Limited
Revenue has grown at a compounded annual rate (CAGR) of 6% over five years, including 10% growth in the latest year. EBITDA rose 1% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Group Pharmaceuticals Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹15.78 Cr | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹10.44 Cr | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Group Pharmaceuticals Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 9.4% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 6.2% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Group Pharmaceuticals are in the company report.
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Group Pharmaceuticals Limited
Group Pharmaceuticals Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations, Pharmaceuticals). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Shree Krishnakeshav Laboratories Limited | ₹170.52 Cr (FY 2025) | •••• | •••• | 13.0% | •••• | Ahmedabad, Gujarat, India |
| Natural Capsules Limited Listed | ₹169.91 Cr (FY 2025) | •••• | •••• | 8.0% | •••• | Bengaluru, Karnataka, India |
| Stericon Pharma Private Limited | ₹169.15 Cr (FY 2025) | •••• | •••• | 21.0% | •••• | Bangalore, Karnataka, India |
| Eurolife Healthcare Private Limited | ₹168.9 Cr (FY 2020) | •••• | •••• | -20.0% | •••• | Thane, Maharashtra, India |
| Medicamen Biotech Limited Listed | ₹168.79 Cr (FY 2025) | •••• | •••• | -7.0% | •••• | New Delhi, Delhi, India |
| Group Pharmaceuticals Limited this company | ₹168.31 Cr (FY 2025) | •••• | •••• | 10.0% | •••• | Thane, Maharashtra, India |
| Tas Med (India) Private Limited | ₹167.95 Cr (FY 2025) | •••• | •••• | 9.0% | •••• | Chandigarh, India |
| Grownbury Pharmaceuticals Private Limited | ₹167.88 Cr (FY 2025) | •••• | •••• | 29.0% | •••• | New Delhi, Delhi, India |
| DWD Pharmaceuticals Limited | ₹166.47 Cr (FY 2025) | •••• | •••• | 10.0% | •••• | Mumbai, Maharashtra, India |
| S. Parikh Pharma Private Limited | ₹165.85 Cr (FY 2024) | •••• | •••• | -6.0% | •••• | Mumbai, Maharashtra, India |
| Srini Pharmaceuticals Private Limited | ₹165.56 Cr (FY 2024) | •••• | •••• | -18.0% | •••• | Hyderabad, Telangana, India |
Peers are the five companies nearest above and the five nearest below Group Pharmaceuticals by revenue in the Pharma industry (Formulations, Pharmaceuticals), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Group Pharmaceuticals Limited
Group Pharmaceuticals Limited is audited by G. K. Gadgil & Co. for the financial year 2024.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| G. K. Gadgil & Co. | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Group Pharmaceuticals Limited
Group Pharmaceuticals has 7 current directors and 17 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Deepak Mohan | Managing Director | 24 May 2024 | 2 Years 4 Months | Current |
| Sunil Attavar Cajaten | Nodal Officer | 17 Sep 2019 | 7 Years 0 Months | Current |
| Ann Valerie Sunil Attavar | Whole-Time Director | 15 Sep 2008 | 18 Years 0 Months | Current |
| Srinivas Gogineni | Director | 08 Aug 2024 | 2 Years 2 Months | Current |
| Nandipur Kallappa Dilip | Director | 08 Aug 2024 | 2 Years 2 Months | Current |
| Jacob Mathew Also directs: Mape Citrus Developers LLP, Jacob Mathew Family Office LLP, Mape Pharmascience LLP and 5 more | Director | 24 May 2024 | 2 Years 4 Months | Current |
Ownership and Shareholding of Group Pharmaceuticals Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Group Pharmaceuticals Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 28 Oct 2025 | Others | ₹20 Cr | Open |
| 04 Mar 2005 | Others | ₹16.25 Cr | Satisfied |
| 27 Mar 2002 | Central Bank of India | ₹5.5 Cr | Satisfied |
| 04 Aug 2001 | Central Bank of India | ₹- | Satisfied |
| 12 Jul 1999 | Central Bank of India | ₹- | Satisfied |
Total charge records: 18 View all charges
Deals & Funding of Group Pharmaceuticals Limited
Group Pharmaceuticals Limited has 3 deals on record (2 acquisitions, 1 rights issue); the latest was in September 2026.
Deals on record (3 of 3)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Sep 2026 | Acquisition | ₹23.7 Cr | Buyer: Jagson Pal Pharmaceuticals Limited. Seller: Group Pharmaceuticals Limited |
| Sep 2025 | Rights issue | ₹10.15 Cr | Investors: MAPE Group, Others - Group Pharmaceuticals Limited, 2 individuals |
| Jan 2002 | Acquisition | ₹28.79 Cr | Buyer: Dr.Reddy's Laboratories Ltd Seller: Group Pharmaceuticals Limited |
Full deal history
All 3 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal Cases of Group Pharmaceuticals Limited
Group Pharmaceuticals Limited has 48 court cases on record: 28 filed by Group Pharmaceuticals, 15 filed against it, 5 where it is another party. 4 cases are pending and 44 are disposed. Status as checked between 21 Sep 2026 and 05 Oct 2026.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 24 | 12 | 2 |
| High courts | 23 | 2 | 2 |
| Supreme Court | 1 | 1 | 0 |
Cases on record (5 of 48)
| Court | Type of case | Party | Status |
|---|---|---|---|
| Bombay High Court | Court case (CRR) | Filed by the company against Anuvaa Softech Private Limited | Disposed |
| Bombay High Court | Court case (COMIP) | Filed by the company against Anuvaa Softech Private Limited | Disposed |
| District court, Mumbai CMM Courts, Maharashtra | Court case (Summary Case) | Filed by the company against Prism Life Sciences Limited | Disposed |
| Bombay High Court | Court case (CHS) | Filed by the company against Lasor Pharmaceuticals Limited | Disposed |
| Bombay High Court | Interim or miscellaneous application | Filed by the company against Zuventus Healthcare Limited | Disposed |
Full case history
All 48 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME Payment Delays by Group Pharmaceuticals Limited
Group Pharmaceuticals Limited has 14 MSME Form 1 returns on record between 2019 and 2024, listing 367 overdue payments to 44 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 44)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Diamond Corporation | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
| Armor Plast Private Limited | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
| Teamlease Regtech Private Limited | •••• | •••• | •••• |
Full MSME payment history
Every supplier, amount and due date from all 14 MSME Form 1 returns is in the company report.
- Every reported supplier due
- Amounts and due dates
- Reasons given in each return
- Period-by-period history
Verified entity values are shown only after access is granted.
Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.
Associated Brands with Group Pharmaceuticals Limited
Group Pharmaceuticals operates two associated brands: Group Pharma and Group Pharmaceuticals Ltd. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Manufactures specialized oral care and healthcare products for consumers and partners worldwide. | grouppharma.com | |
| Oral care and healthcare product manufacturing and exporting. | grouppharma.in |
Employees and EPFO Compliance at Group Pharmaceuticals Limited
Group Pharmaceuticals Limited has a workforce of 739 employees as of Mar 08, 2025.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
CIN History of Group Pharmaceuticals Limited
Group Pharmaceuticals has one previous CIN (Corporate Identification Number): U24239MH1980PTC022889. The current CIN is U24239MH1980PLC022889, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24239MH1980PLC022889 | Current |
| U24239MH1980PTC022889 | Previous |
Recent Activity on Group Pharmaceuticals Limited
Group Pharmaceuticals Limited has 25 board changes on record since 2008: 9 appointments and 16 cessations. The latest: Nikhil Kaushik was appointed as Additional Director on 29 Sep 2025.
58 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Group Pharmaceuticals Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Group Pharmaceuticals Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Group Pharmaceuticals Limited
Group Pharmaceuticals has 12 GST registrations: 2 active and 10 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAACG8723H1ZK | Maharashtra | Active | 01 Jul 2017 |
| 29AAACG8723H1ZG | Karnataka | Active | 01 Jul 2017 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Group Pharmaceuticals Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Group Pharmaceuticals Limited
Group Pharmaceuticals is an active public limited company based in Thane, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 24 July 1980 (46+ years old) and is registered under CIN U24239MH1980PLC022889.
Group Pharmaceuticals reported revenue of ₹168.31 Cr for FY 2025 (up 10% YoY).
Group Pharmaceuticals has 7 current directors:
- Deepak Mohan - Managing Director
- Ann Valerie Sunil Attavar - Whole-Time Director
- Srinivas Gogineni - Director
- Nandipur Kallappa Dilip - Director
- Jacob Mathew - Director
- Nikhil Kaushik - Additional Director
- Sunil Attavar Cajaten - Nodal Officer
Group Pharmaceuticals reported a net profit of ₹10.44 Cr (net margin 6.2%) and EBITDA of ₹15.78 Cr (EBITDA margin 9.4%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Group Pharmaceuticals is 9% over three years and 6% over five years. In the latest year (FY 2025) revenue rose 10%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Group Pharmaceuticals is 27AAACG8723H1ZK, registered in Maharashtra. The company has 12 GST registrations in all, of which 2 are active and 10 are cancelled or inactive. Other active GSTINs include 29AAACG8723H1ZG (Karnataka).
The CIN (Corporate Identification Number) of Group Pharmaceuticals is U24239MH1980PLC022889. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Group Pharmaceuticals has 48 court cases on record: 28 filed by the company and 15 filed against it. 4 are pending. Most are in the district courts.
Group Pharmaceuticals was incorporated on 24 July 1980, making it 46+ years old. It is registered with the Registrar of Companies, Mumbai.
Group Pharmaceuticals has 3 deals on record (2 acquisitions, 1 rights issue); the latest was in September 2026.
The peers of Group Pharmaceuticals by revenue are Shree Krishnakeshav Laboratories Limited, Natural Capsules Limited, Stericon Pharma Private Limited, Eurolife Healthcare Private Limited, Medicamen Biotech Limited and 5 more, all in the Pharma industry (Formulations, Pharmaceuticals).
Nikhil Kaushik was appointed as Additional Director on 29 Sep 2025. Nikhil Kaushik was appointed as CEO on 12 May 2025. Annasagaram Balagurunath Ramkumar ceased to be Additional Director on 20 Sep 2024. Group Pharmaceuticals has 25 board changes on record in total.